
Karen K Winer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1562485/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of periprocedural subcutaneous parathyroid hormone on control of hypocalcaemia in APSâ€1/APECED patients undergoing invasive procedures. Clinical Endocrinology, 2021, 94, 377-383.	1.2	3
2	Therapy with PTH 1–34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27Âyears at a single tertiary care center. Bone, 2021, 149, 115977.	1.4	9
3	Autosomal Dominant Hypocalcemia Type 1. , 2020, , 63-71.		0
4	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	5.8	52
5	Advances in the treatment of hypoparathyroidism with PTH 1–34. Bone, 2019, 120, 535-541.	1.4	30
6	Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism. Journal of Pediatrics, 2018, 203, 391-399.e1.	0.9	36
7	Does PTH Replacement Therapy Improve Quality of Life in Patients With Chronic Hypoparathyroidism?. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2752-2755.	1.8	12
8	Hypoparathyroidism. Nature Reviews Disease Primers, 2017, 3, 17055.	18.1	142
9	Association Between Linear Growth and Bone Accrual in a Diverse Cohort of Children and Adolescents. JAMA Pediatrics, 2017, 171, e171769.	3.3	112
10	Relative Skeletal Maturation and Population Ancestry in Nonobese Children and Adolescents. Journal of Bone and Mineral Research, 2017, 32, 115-124.	3.1	15
11	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight, 2016, 1, .	2.3	219
12	Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2313-2324.	1.8	151
13	Perspectives on the Search for a True Physiologic Replacement Therapy for Hypoparathyroidism. European Endocrinology, 2016, 12, 47.	0.8	3
14	Corrigenda. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2800-2800.	1.8	217
15	Polyglandular autoimmune syndrome type I – a novel AIRE mutation in a North American patient. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 1257-60.	0.4	9
16	Age-Based Reference Ranges for Annual Height Velocity in US Children. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2104-2112.	1.8	90
17	Effects of Pump versus Twice-Daily Injection Delivery of Synthetic Parathyroid Hormone 1-34 in Children with Severe CongenitalÂHypoparathyroidism. Journal of Pediatrics, 2014, 165, 556-563.e1.	0.9	96
18	Revised Reference Curves for Bone Mineral Content and Areal Bone Mineral Density According to Age and Sex for Black and Non-Black Children: Results of the Bone Mineral Density in Childhood Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3160-3169.	1.8	396

KAREN K WINER

#	Article	IF	CITATIONS
19	Long-Term Treatment of 12 Children with Chronic Hypoparathyroidism: A Randomized Trial Comparing Synthetic Human Parathyroid Hormone 1-34 versus Calcitriol and Calcium. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2680-2688.	1.8	158
20	Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in Children. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1265-1273.	1.8	368
21	Clinical Vignette: PTH(1–34) Replacement Therapy in a Child With Hypoparathyroidism Caused by a Sporadic Calcium Receptor Mutation. Journal of Bone and Mineral Research, 2009, 24, 964-973.	3.1	72
22	Effects of Once <i>Versus</i> Twice-Daily Parathyroid Hormone 1–34 Therapy in Children with Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3389-3395.	1.8	128
23	Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1–34)VersusCalcitriol and Calcium. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4214-4220.	1.8	287
24	A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1–34 in Treatment of Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3480-3486.	1.8	138
25	A Ca2+-Sensing Receptor Mutation Causes Hypoparathyroidism by Increasing Receptor Sensitivity to Ca2+ and Maximal Signal Transduction1. Pediatric Research, 1997, 42, 443-447.	1.1	31
26	Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Human Molecular Genetics, 1996, 5, 601-606.	1.4	189
27	Synthetic Human Parathyroid Hormone 1-34 vs Calcitriol and Calcium in the Treatment of Hypoparathyroidism. JAMA - Journal of the American Medical Association, 1996, 276, 631.	3.8	149